Endpoints News· @endpts · X·· 20 天前AI 评分52
AI 导读
安斯泰来从Audax Biosciences获得一款临床前IL-12抗癌药物的选择权,2.85亿美元涵盖首付款与行权费用。该交易标的尚处于临床前阶段。
正文
Astellas took an option on Audax’s preclinical cancer drug, with $285M covering the upfront and exercise fees. https://endpoints.news/astellas-buys-option-to-preclinical-il-12-cancer-drug-from-audax-biosciences/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com